Results of a study investigating acalabrutinib combined with venetoclax and rituximab for treatment of MCL.
Home / Resource Library / Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis